Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as an intravenous solution for intravenous use. It is employed in the treatment of hairy cell leukemia, a rare B‑cell malignancy, and is administered under specialist supervision.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Leustatin is shipped in temperature‑controlled packaging to maintain product integrity during transit.

Cladribine is a purine nucleoside analog used in hematologic malignancies, specifically targeting B‑cell disorders.

Hairy cell leukemia: induces durable remission by depleting malignant lymphocytes.

Cladribine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during and after treatment. - Fever: transient elevations in body temperature. - Anemia: reduced red blood cell count causing pallor. - Headache: occasional mild cranial discomfort. - Infection risk: increased susceptibility to bacterial infections.

Serious or Rare Side Effects: - Severe neutropenia: profound drop in neutrophils leading to life‑threatening infections. - Opportunistic infections: reactivation of latent viruses or fungal disease. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Autoimmune hemolysis: immune‑mediated destruction of red blood cells. - Hepatic toxicity: elevated liver enzymes indicating liver stress. - Severe allergic reactions: anaphylaxis or severe cutaneous reactions.

Prior to initiating therapy, several safety considerations should be addressed.

Monitor blood counts: perform regular CBC to detect neutropenia or anemia. Assess infection risk: screen for active infections and consider prophylaxis. Pregnancy considerations: avoid use unless benefits outweigh potential fetal risks. Renal function: evaluate kidney function and adjust if impairment is present. Concomitant immunosuppressants: use with caution due to additive marrow suppression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other agents that affect bone marrow or immune function.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may cause excessive marrow toxicity. - Live attenuated vaccines: risk of uncontrolled infection. - Strong immunosuppressive agents: heightened infection susceptibility.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: possible reduced immunogenicity. - Antibiotics for infection prophylaxis: monitor for additive hematologic effects. - Allopurinol: increased risk of tumor lysis syndrome; monitor uric acid levels.